Form 4: Vigil Neuroscience CMO Converts Options Post-Sanofi Merger

Vigil Neuroscience's Chief Medical Officer, Petra Kaufmann, converted her stock options into cash and contingent value rights following the company's merger with Sanofi.

Summary

• Reports the disposition of stock options by Petra Kaufmann, Chief Medical Officer of Vigil Neuroscience, Inc.
• The disposition occurred due to the merger of Vigil Neuroscience, Inc. with Vesper Acquisition Sub Inc., a wholly-owned subsidiary of Sanofi.
• The merger became effective on August 5, 2025, with Vigil Neuroscience continuing as a wholly-owned subsidiary of Sanofi.
• Each outstanding share of Vigil Neuroscience Common Stock was converted into $8.00 in cash plus one Contingent Value Right (CVR) for an additional $2.00, contingent on a clinical milestone.
• All unvested stock options were accelerated and fully vested at the effective time of the merger.
• Stock options with an exercise price below the $8.00 Closing Amount were cancelled and converted into a cash payment (total shares multiplied by the excess of the Closing Amount over the exercise price) and one CVR per share.
• Petra Kaufmann's 144,000 stock options with an exercise price of $2.19 and 330,000 stock options with an exercise price of $3.14 were converted.

Sentiment

Score: 7

Explanation: The filing reports the successful completion of a merger for Vigil Neuroscience, resulting in liquidity for shareholders and option holders, including the reporting person. The CVR provides potential additional value. While the company ceases to be independent, the transaction appears to be a positive outcome for its equity holders.

Positives

• Unvested stock options were accelerated and fully vested at the effective time of the merger.
• Stock options with an exercise price below the merger consideration were converted into cash and CVRs, providing liquidity and potential future upside.
• The merger consideration of $8.00 per share plus a $2.00 CVR represents a defined value for shareholders and option holders.

Negatives

• Vigil Neuroscience, Inc. ceased to be an independent publicly traded entity, becoming a wholly-owned subsidiary of Sanofi.

Future Outlook

The future outlook for Vigil Neuroscience, Inc. is now integrated with Sanofi's strategic plans, as it operates as a wholly-owned subsidiary. The contingent value right (CVR) offers potential future payment based on a specific clinical milestone.

Industry Context

This merger reflects the ongoing consolidation trend within the biotechnology and pharmaceutical sectors, where larger pharmaceutical companies acquire smaller biotech firms to gain access to promising pipelines and specialized expertise, particularly in neuroscience.

Comparison to Industry Standards

• The merger consideration of $8.00 cash plus a $2.00 CVR per share is a common structure in biotech acquisitions, allowing acquirers to manage risk while providing potential upside to selling shareholders based on clinical success. For example, similar CVR structures have been seen in acquisitions like Bristol Myers Squibb's acquisition of MyoKardia or Sanofi's previous acquisitions, where milestone payments are tied to regulatory approvals or sales targets.
• The acceleration of unvested options is also standard practice in change-of-control events to ensure executive alignment and compensation.

Stakeholder Impact

• Shareholders: Received $8.00 cash per share and one CVR for $2.00, providing liquidity and potential future upside.
• Employees (specifically option holders like the CMO): Unvested options accelerated and converted to cash and CVRs, providing immediate value and potential future payments.
• Company (Vigil Neuroscience): Ceased to be an independent public entity, becoming a wholly-owned subsidiary of Sanofi, integrating its operations and pipeline into a larger pharmaceutical company.

Next Steps

• Satisfaction of the clinical milestone for the Contingent Value Right (CVR) payment.

Key Dates

Keywords

Vigil Neuroscience, VIGL, Sanofi, Merger, Acquisition, Stock Options, Form 4, Insider Transaction, Contingent Value Right, CVR, Biotechnology, Pharmaceuticals